(Q37402181)

20 August 2017

1 reference

title

Donepezil in severe Alzheimer's disease (English)

1 reference

20 August 2017

0 references

1

Bengt Winblad

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

American Journal of Alzheimer's Disease & Other Dementias

20 August 2017

published in

1 reference

20 August 2017

volume

24

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

185-192

1 reference

Alzheimer Disease in the US Population

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Management of glaucoma: focus on pharmacological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Recommendations for best practices in the treatment of Alzheimer's disease in managed care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Donepezil preserves cognition and global function in patients with severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

Behavioural and Psychological Symptoms of Dementia - Agitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509332094

21 January 2018

Identifiers

DOI

10.1177/1533317509332094

1 reference

20 August 2017

1 reference